FACEHBI study of early Alzheimer's detection expands
Fundació ACE will renew FACEHBI study (ACE Healthy Brain
With this expansion, the study, which was launched in 2014 and which carries out an exhaustive medical follow-up of 200 healthy volunteers, becomes one of the most complete of these characteristics to date.
The study, which is part of the Prevention and Early Diagnosis Unit of the entity, has managed to establish a predictive system to determine the risk of developing pathologies related to dementia such as Alzheimer's disease, vascular, psycho-affective or other degenerative diseases such as dementia with Lewy bodies.
The 200 FACEHBI participants annually perform very thorough medical tests that include a neurological and neuropsychological examination, an MRI and a blood biomarker test.
To these tests are added already recognized biomarkers that detect amyloid protein such as PET or Tau protein analysis, among others. Another promising new line of research that has begun in recent years is related to the intestinal bacterial flora and its influence on neurodegeneration.
FACEHBI has been developed successfully so far. The recruitment of the 200 participants was completed in just fifteen months and the adherence rate, after four years of follow-up, is above 80%. In addition, there have been no unforeseen or adverse circumstances related to the study procedures and both the methodology of the analysis and the baseline data of the participants have already been published in prestigious scientific journals with a high impact factor.